PRIMARY STUDY
Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips
Key Findings: A once-daily dose of THCV and CBD-infused mucoadhesive strips resulted in clinically significant weight loss and decreases in abdominal girth, systolic blood pressure, and total and LDL cholesterol.
Type of Study: Double Blind Clinical Trial
Study Result: Positive
Research Location(s): United States
Year of Pub: 2025
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1 antagonist
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Sublingual/Oromucosal
Cannabinoid Ratio: (THCV : CBD) 1 : 1 
Dosage Form: Mucoadhesive oral strips
Dosing Regimen: Low dosage: 8 mg THCV/10 mg CBD once daily Higher dosage: 8 mg THCV/10 mg CBD twice daily
Starting Dose: Either low or high dose only.
Titration: N/A
Maximum Dose: 16 mg THCV/20 mg CBD daily dose
Treatment Duration: 90 days
Clinical Relevance: 16 mg/20 mg daily dose was superior for weight loss (the study's primary outcome focus)
Adverse Events: Minor
Additional Notes: Parallel Dose Comparison
Citation: Smith GL. Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips. Cannabis. 2025 Feb 1;8(1):109-120. doi: 10.26828/cannabis/2024/000206. PMID: 39968488; PMCID: PMC11831893.
